Literature DB >> 11755609

High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study.

G Walldius1, I Jungner, I Holme, A H Aastveit, W Kolar, E Steiner.   

Abstract

BACKGROUND: Apolipoprotein B (apoB) and apolipoprotein A-I (apoA-I) are thought to be better predictors of acute myocardial infarction than total cholesterol and LDL-cholesterol. We investigated whether apoB and apoA-I are predictors of risk of fatal myocardial infarction. We also aimed to establish whether apoB and apoA-I add further information about risk of fatal myocardial infarction to that obtained with total cholesterol, triglycerides, and LDL-cholesterol.
METHODS: We recruited 175553 individuals mainly from screening programmes. We measured concentrations of apoB, apoA-I, total cholesterol, and triglycerides, and calculated apoB/apoA-I ratio and concentrations of LDL-cholesterol and HDL-cholesterol. The relation between death from acute myocardial infarction and initial values for apoB, apoA-I, and the other lipids was examined.
FINDINGS: Mean follow-up was 66.8 months (SD 41.3) for 98722 men and 64.4 months (41.4) for 76831 women. 864 men and 359 women had fatal myocardial infarction. In univariate analyses adjusted for age and in multivariate analyses adjusted for age, total cholesterol, and triglycerides, the values for apoB and apoB/apoA-I ratio were strongly and positively related to increased risk of fatal myocardial infarction in men and in women. ApoA-I was noted to be protective. In multivariate analysis, apoB was a stronger predictor of risk than LDL-cholesterol in both sexes.
INTERPRETATION: Although LDL-cholesterol and HDL-cholesterol are known risk factors, we suggest that apoB, apoB/apoA-I, and apoA-I should also be regarded as highly predictive in evaluation of cardiac risk. Although increased throughout the range of values of LDL-cholesterol, apoB and apoA-I might be of greatest value in diagnosis and treatment in men and women who have common lipid abnormalities, but have normal or low concentrations of LDL-cholesterol.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11755609     DOI: 10.1016/S0140-6736(01)07098-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  262 in total

1.  The effects of resistance training on ApoB/ApoA-I ratio, Lp(a) and inflammatory markers in patients with type 2 diabetes.

Authors:  Nikolaos P E Kadoglou; Grigorios Fotiadis; Zoi Athanasiadou; Ioulia Vitta; Stylianos Lampropoulos; Ioannis S Vrabas
Journal:  Endocrine       Date:  2012-03-11       Impact factor: 3.633

2.  Association of apolipoprotein A1 and B with kidney function and chronic kidney disease in two multiethnic population samples.

Authors:  Oemer-Necmi Goek; Anna Köttgen; Ron C Hoogeveen; Christie M Ballantyne; Josef Coresh; Brad C Astor
Journal:  Nephrol Dial Transplant       Date:  2012-01-28       Impact factor: 5.992

3.  Using apolipoprotein B to manage dyslipidemic patients: time for a change?

Authors:  Charles R Harper; Terry A Jacobson
Journal:  Mayo Clin Proc       Date:  2010-05       Impact factor: 7.616

4.  Lipid profiles and the risk of endometrial cancer in the Swedish AMORIS study.

Authors:  Divya Seth; Hans Garmo; Annette Wigertz; Lars Holmberg; Niklas Hammar; Ingmar Jungner; Mats Lambe; Göran Walldius; Mieke Van Hemelrijck
Journal:  Int J Mol Epidemiol Genet       Date:  2012-05-15

5.  Prothrombotic markers in asymptomatic dyslipidemic subjects.

Authors:  David Karasek; Helena Vaverkova; Milan Halenka; Dagmar Jackuliakova; Zdenek Frysak; Ludek Slavik; Dalibor Novotny
Journal:  J Thromb Thrombolysis       Date:  2011-01       Impact factor: 2.300

6.  Nontraditional risk factors for cardiovascular disease and visceral adiposity index among different body size phenotypes.

Authors:  T Du; J Zhang; G Yuan; M Zhang; X Zhou; Z Liu; X Sun; X Yu
Journal:  Nutr Metab Cardiovasc Dis       Date:  2014-08-07       Impact factor: 4.222

Review 7.  A clinical prescription for heart health in midlife women.

Authors:  Chrisandra Shufelt; Erika Dutra; Tina Torbati; Tina Ramineni
Journal:  Maturitas       Date:  2018-11-12       Impact factor: 4.342

8.  Antiobesity and vasoprotective effects of resveratrol in apoE-deficient mice.

Authors:  Seon-Min Jeon; Seung-A Lee; Myung-Sook Choi
Journal:  J Med Food       Date:  2014-01-16       Impact factor: 2.786

9.  Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians.

Authors:  Michel P Hermans; Jean-Charles Fruchart
Journal:  Ther Adv Chronic Dis       Date:  2011-09       Impact factor: 5.091

10.  Major lipids, apolipoproteins, and risk of vascular disease.

Authors:  Emanuele Di Angelantonio; Nadeem Sarwar; Philip Perry; Stephen Kaptoge; Kausik K Ray; Alexander Thompson; Angela M Wood; Sarah Lewington; Naveed Sattar; Chris J Packard; Rory Collins; Simon G Thompson; John Danesh
Journal:  JAMA       Date:  2009-11-11       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.